Congratulations to Paul Evans for being named one of the Top 50 Healthcare Technology CEOs of 2024! With Paul’s leadership, Velocity continues to redefine how clinical trials are conducted — leveraging VISION technology, centralization, and global site integration to accelerate drug development. His recognition by The Healthcare Technology Report is a nod to his vision … Read more
Velocity’s team contributed to the new Association of Clinical Research Professionals (ACRP) comprehensive whitepaper, titled ‘Responsible Oversight of Artificial Intelligence for Clinical Research Professionals.’ The development of our VISION technology has coincided with the proliferation of AI and large language models (LLMs). For recruitment purposes, these tools have improved patient-trial matching, automated outreach, and enabled … Read more
Robert Cupelo, MD, Principal Investigator in Syracuse, NY, shares his firsthand insights into the evolving landscape of Alzheimer’s treatment. Nearly two years after the FDA’s approval of lecanemab (Leqembi), and with the subsequent approval of donanemab (Kisunla), researchers are making crucial steps forward in the fight against disease progression and for disease prevention. In this … Read more
A new Fierce Biotech article features insights from Paul Evans on what to expect for clinical research in 2025. Topics include rising costs and uncertain regulations, as well as the continued emergence of site networks, AI-driven efficiency (with technology built “by trial sites, for trial sites”), and enhanced diversity initiatives. Read the article here: https://www.fiercebiotech.com/cro/clinical-trials-industry-set-uncertain-interconnected-2025-according-velocity-clinical-research
Rising costs, evolving regulations, and the unstoppable growth of AI are set to shape clinical trials in 2025. How will sites, new tech, promising obesity drugs, and shifting policies affect our industry? Read this article from Paul Evans featured on PharmiWeb: https://www.pharmiweb.com/article/2025-clinical-trials-outlook-six-industry-trends-to-expect
Congratulations to Henrik Watz, MD, on his exceptional presentation at the 2024 European Respiratory Society (ERS) ADVENT COPD Symposia! Dr. Watz, Medical Director and Principal Investigator at Velocity Clinical Research in Ahrensburg, Germany, joined Drs. Mona Bafadhel and Alberto Papi for a dynamic discussion, A Breath of Fresh Air: A Greater Understanding of COPD With … Read more
Velocity Clinical Research, the leading fully integrated clinical site organization, announces the appointment of Renata Berardocco as Executive Vice President and Managing Director for the Latin America (LATAM) region. Renata has nearly two decades of experience in senior leadership roles and joins from Fortrea, where she led Clinical Operations Delivery and Clinical Projects. LATAM represents … Read more
For decades, research into respiratory health has centered on conditions such as asthma and chronic obstructive pulmonary disease (COPD), predominantly because of their high prevalence. However, the incidence of respiratory diseases is increasing globally, with lesser-researched but equally debilitating conditions such as interstitial lung disease, pulmonary sarcoidosis, and pneumoconiosis affecting health statuses worldwide. While clinical … Read more
Another outstanding achievement for Henrik Watz, MD, PhD, and our team in Ahrensburg, Germany! They led enrollment for a global chronic obstructive pulmonary disease (COPD) trial, more than doubling the enrollment of the next highest-performing site. Congratulations to Dr. Watz and our Ahrensburg team! Learn more about our respiratory capabilities >
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, presented late-breaking data for Iqirvo® (elafibranor), Ipsen’s treatment for primary biliary cholangitis (PBC), at American Association for the Study of Liver Diseases (AASLD). “Over three years, Iqirvo data suggest sustained efficacy and support the safety profile of the medicine,” said Dr. Kowdley. “Importantly, when patients tell me they … Read more